.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC02_Fluorouracil.Fluorouracil .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01B_Antimetabolites.L01BC02_Fluorouracil.Fluorouracil| name: | Fluorouracil |
| ATC code: | L01BC02 | route: | intravenous |
| n-compartments | 2 |
Fluorouracil (5-FU) is an antimetabolite chemotherapeutic agent widely used in the treatment of various cancers, including colorectal, breast, gastric, pancreatic, and head and neck cancers. It interferes with DNA synthesis and cell division by inhibiting thymidylate synthase. 5-FU has been used for decades and remains an important drug in oncology, typically administered intravenously.
Pharmacokinetic parameters reported for adult cancer patients receiving intravenous 5-FU.
Ismael, G, et al., & Jackisch, C (2012). Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial. The Lancet. Oncology 13(9) 869–878. DOI:10.1016/S1470-2045(12)70329-7 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22884505
Rietveld, PCS, et al., & Koolen, SLW (2024). Intraperitoneal pharmacokinetics of systemic oxaliplatin, 5-fluorouracil and bevacizumab in patients with colorectal peritoneal metastases. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 176 116820–None. DOI:10.1016/j.biopha.2024.116820 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38810398
Batey, MA, et al., & Boddy, AV (2002). Population pharmacokinetics of adjuvant cyclophosphamide, methotrexate and 5-fluorouracil (CMF). European journal of cancer (Oxford, England : 1990) 38(8) 1081–1089. DOI:10.1016/s0959-8049(02)00024-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/12008196